CT-STARWOOD-HOTELS
29.4.2016 12:11:17 CEST | Business Wire | Press release
Tribute Portfolio, a collection of independent hotels and resorts from Starwood Hotels & Resorts Worldwide, Inc. (NYSE: HOT), today announced three new signings, bringing the brand’s footprint to 20 properties worldwide, exactly double the original growth projection for its first year. Continuing to global expansion with its first-ever property in China and continuing to expand in Florida with signings in Tampa and Sarasota, Tribute Portfolio maintains its steadfast position as having the fastest takeoff of any Starwood brand, ever, while also celebrating its individuality through innovative social media and brand partnership strategies. With a long runway to grow, Tribute Portfolio continues to add exceptional properties around the globe that offer guests and owners the ability to “Stay Independent.”
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160429005399/en/
From the Bustling City of Shanghai to the Sunny Coast of Florida
With momentum steadily building for the one year old brand, Tribute Portfolio once again answers consumer demand with the addition of three properties in Shanghai, Sarasota and Tampa. When surveying Starwood Preferred Guest® (SPG) Members, the brand found that 62% would be very interested in staying at a Tribute Portfolio hotel in Shanghai. Answering this call, Tribute Portfolio will expand its footprint in Asia by adding a property in the cosmopolitan Chinese city. Members also told the brand that beach destinations remain at the top of their list, particularly in Florida. As a result, the brand will open an additional two new properties in the Sunshine State: a 323-room hotel in Tampa, and The Sarasota Modern, a Tribute Portfolio Hotel, in Sarasota.
Giving Guests -- And Owners -- What They Want
From boutique resorts to urban destination properties, Tribute Portfolio gives guests access to outstanding upper upscale hotels with an independent spirit, all while benefitting from the award-winning SPG® program. Built and fueled by consumer preferences, Tribute Portfolio carves out its distinction in the category through its close collaboration with the SPG community.
“The independent hotel segment has continued to grow exponentially, with consumers increasingly desiring travel to hotels and resorts that don’t fall under a cookie-cutter brand,” said Dave Marr, Global Brand Leader, Tribute Portfolio. “This trend, coupled with the strength and support of our owner and developer community, has contributed to the meteoric growth of the brand and its continued success as we enter our second year.”
Tribute Portfolio debuted in April 2015 with its first hotel, the Royal Palm South Beach Miami, and has since opened eight additional properties: the Great Northern Hotel in London, UK; The Kiroro Resort in Hokkaido, Japan; The Hermitage in Jakarta, Indonesia; the SLS Las Vegas in Las Vegas, NV; The Riviera Palm Springs in Palm Springs, CA; Avenue of the Arts in Costa Mesa, CA; and Le Dokhan’s and Le Metropolitan, both in Paris. Future locations include Coral Gables, FL; Fort Lauderdale, FL; Tampa, FL; Sarasota, FL; Asheville, NC; Nashville, Tennessee; Savannah, GA; Charleston, SC; Denver, CO; Shanghai, China; and Quebec City, Canada.
With flexibility and individuality at its core, Tribute Portfolio has also struck a chord with the owner/developer community, enabling them to maintain their independent spirit, while benefiting from Starwood's powerful distribution, loyalty and sales platforms.
"The rapid rate of growth that Tribute Portfolio has achieved comes as no surprise, combining Starwood’s robust sales, marketing and loyalty programs with the flair and individualism of the independent boutique hotelier,” said Jeremy Robson, Owner-Operator, Great Northern Hotel, London. “I am delighted that Great Northern Hotel is now part of the Tribute Portfolio franchise, and the abundant positive feedback we get from our customers indicates they feel the same. I expect the brand’s global expansion to continue accelerating way beyond the most optimistic of forecasts.”
Reaching Socially Connected, Independent-Minded Travelers
Shifting focus from being the expert on the destination, Tribute Portfolio instead elevates the notion that guests seek out independent hotels because the hotels themselves can be the destination. To capture this, each Tribute Portfolio property features a noteworthy selection of #independentmoments : distinct design details and experiences that illustrate what guests love about “staying independent.” In addition, Tribute Portfolio is the first hotel brand to partner with consumer shopping service, LIKEtoKNOW.it , enabling travelers to translate their wanderlust into room bookings at two of the Tribute Portfolio brand’s newest hotels – Le Metropolitan and Le Dokhan’s – directly by “liking” a photo on Instagram. Finally, the brand also launched a new partnership with Pitchfork that will bring unique pop-up music activations to several Tribute Portfolio properties worldwide, exposing guests to emerging artists and established pioneers who apply a true independent mindset to their musical craft, regardless of genre.
For more information, please visit www.tributeportfolio.com .
# # #
About Tribute Portfolio
Launched
in April 2015 as Starwood’s 10th brand and second collection of
independent hotels, Tribute Portfolio is comprised of exceptional
independent hotels around the globe, offering guests and owners the
ability to “Stay Independent.” From boutique resorts to urban
destination properties, guests can enjoy access to outstanding upper
upscale hotels with an indie spirit while benefitting from the
award-winning Starwood Preferred Guest (SPG) program. For more
information on Tribute Portfolio, please visit www.tributeportfolio.com
.
Follow along to Stay Independent: @TributePortfolio
on Instagram, @TributePRTFLO
on Twitter, tumblr.com/TributePortfolio
and www.facebook.com/TributePortfolio
.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160429005399/en/
Contact:
Starwood Hotels & Resorts
Media Contacts
Julien
Guitard, +32 2 204 5160
Associate Director Communications – Europe,
Africa & Middle East
Julien.Guitard@starwoodhotels.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom